BioCentury | Feb 19, 2021
Product Development

Phase III Astellas readout marks step forward for non-hormonal menopause therapies

Astellas’ bet on women’s health company Ogeda is paying off with a pair of positive Phase III readouts for its first-in-class, non-hormonal menopause therapy. Astellas Pharma Inc. (Tokyo:4503) said Friday the Phase III SKYLIGHT 1 and...
BioCentury | Feb 18, 2021
Finance

Advent raises next funds, taps Midwest innovation

Advent Life Sciences’ latest funds include a tie-up with the Harrington Discovery Institute, providing the trans-Atlantic VC with an early look at innovation coming out of the Cleveland-area accelerator. On Thursday, Advent announced the close of...
BioCentury | Feb 18, 2021
Finance

With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs

The founders of Adjuvant Capital believe they’ve found a way to apply the VC model to global public health investing and generate returns in an area other VCs have largely eschewed. Launched in 2019 by...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) said Chairman James Mullen will succeed Cynthia Collins as CEO after she steps down on Feb. 15. Collins had held the role since August 2019. Mullen, who was...
BioCentury | Feb 9, 2021
Finance

Illumina unveils latest entrants to accelerator in SF, U.K.

Genomics player Illumina has added nine more start-ups to the stable of genomics newcos residing at its Illumina Accelerator. On Monday, Illumina Inc. (NASDAQ:ILMN) announced the latest round of companies selected in the accelerator’s global...
BioCentury | Feb 6, 2021
Deals

Feb. 5 Quick Takes: Veracyte taking out Decipher in cancer dx merger; plus V-Bio, Branson-and-Me, Elucidata, Osel

Veracyte Inc. (NASDAQ:VCYT) is acquiring fellow cancer diagnostics company Decipher Biosciences Inc. for $600 million in a cash-and-stock deal. Tina Nova, Decipher’s president and CEO, will join Veracyte as general manager, urologic cancers.  First close, second fundV-Bio...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

Gene and cell therapy company Sana Biotechnology Inc. proposed terms for an IPO on NASDAQ in which it hopes to sell 15 million shares at $20-$23. At the midpoint, the company would raise $322.5 million...
BioCentury | Jan 15, 2021
Politics, Policy & Law

New relevance, old guard: Biden throws weight behind science, puts Lander in Cabinet, keeps Collins at NIH

President-elect Joe Biden is raising the profile of science in his administration by elevating the role of presidential science advisor to a Cabinet position, naming the Broad Institute’s Eric Lander to the post, and nominating...
BioCentury | Jan 13, 2021
Management Tracks

Spark vet High joins AskBio; plus Rotthier to lead Sanofi API unit and moves at Immunovant, Innocoll

The Asklepios BioPharmaceutical Inc. (AskBio) unit of Bayer AG (Xetra:BAYN) hired Spark Therapeutics Inc. alum Katherine High as president, therapeutics. As president and head of R&D at Spark, High led the development and regulatory approval of Luxturna...
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

Pacific Biosciences of California Inc. (NASDAQ:PACB) filled two newly created posts via the hiring of a pair of Illumina Inc. (NASDAQ:ILMN) veterans: Mark Van Oene as COO and Peter Fromen as chief commercial officer. Van Oene...
Items per page:
1 - 10 of 4444
BioCentury | Feb 19, 2021
Product Development

Phase III Astellas readout marks step forward for non-hormonal menopause therapies

Astellas’ bet on women’s health company Ogeda is paying off with a pair of positive Phase III readouts for its first-in-class, non-hormonal menopause therapy. Astellas Pharma Inc. (Tokyo:4503) said Friday the Phase III SKYLIGHT 1 and...
BioCentury | Feb 18, 2021
Finance

Advent raises next funds, taps Midwest innovation

Advent Life Sciences’ latest funds include a tie-up with the Harrington Discovery Institute, providing the trans-Atlantic VC with an early look at innovation coming out of the Cleveland-area accelerator. On Thursday, Advent announced the close of...
BioCentury | Feb 18, 2021
Finance

With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs

The founders of Adjuvant Capital believe they’ve found a way to apply the VC model to global public health investing and generate returns in an area other VCs have largely eschewed. Launched in 2019 by...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) said Chairman James Mullen will succeed Cynthia Collins as CEO after she steps down on Feb. 15. Collins had held the role since August 2019. Mullen, who was...
BioCentury | Feb 9, 2021
Finance

Illumina unveils latest entrants to accelerator in SF, U.K.

Genomics player Illumina has added nine more start-ups to the stable of genomics newcos residing at its Illumina Accelerator. On Monday, Illumina Inc. (NASDAQ:ILMN) announced the latest round of companies selected in the accelerator’s global...
BioCentury | Feb 6, 2021
Deals

Feb. 5 Quick Takes: Veracyte taking out Decipher in cancer dx merger; plus V-Bio, Branson-and-Me, Elucidata, Osel

Veracyte Inc. (NASDAQ:VCYT) is acquiring fellow cancer diagnostics company Decipher Biosciences Inc. for $600 million in a cash-and-stock deal. Tina Nova, Decipher’s president and CEO, will join Veracyte as general manager, urologic cancers.  First close, second fundV-Bio...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

Gene and cell therapy company Sana Biotechnology Inc. proposed terms for an IPO on NASDAQ in which it hopes to sell 15 million shares at $20-$23. At the midpoint, the company would raise $322.5 million...
BioCentury | Jan 15, 2021
Politics, Policy & Law

New relevance, old guard: Biden throws weight behind science, puts Lander in Cabinet, keeps Collins at NIH

President-elect Joe Biden is raising the profile of science in his administration by elevating the role of presidential science advisor to a Cabinet position, naming the Broad Institute’s Eric Lander to the post, and nominating...
BioCentury | Jan 13, 2021
Management Tracks

Spark vet High joins AskBio; plus Rotthier to lead Sanofi API unit and moves at Immunovant, Innocoll

The Asklepios BioPharmaceutical Inc. (AskBio) unit of Bayer AG (Xetra:BAYN) hired Spark Therapeutics Inc. alum Katherine High as president, therapeutics. As president and head of R&D at Spark, High led the development and regulatory approval of Luxturna...
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

Pacific Biosciences of California Inc. (NASDAQ:PACB) filled two newly created posts via the hiring of a pair of Illumina Inc. (NASDAQ:ILMN) veterans: Mark Van Oene as COO and Peter Fromen as chief commercial officer. Van Oene...
Items per page:
1 - 10 of 4444